Bluejay Diagnostics (BJDX) Competitors $3.45 -0.08 (-2.27%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$3.56 +0.11 (+3.19%) As of 02/21/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsShort InterestTrends BJDX vs. PSTV, STRR, CTCX, NUWE, CHEK, TNON, SINT, TTOO, HSCS, and AMIXShould you be buying Bluejay Diagnostics stock or one of its competitors? The main competitors of Bluejay Diagnostics include Plus Therapeutics (PSTV), Star Equity (STRR), Carmell (CTCX), Nuwellis (NUWE), Check-Cap (CHEK), Tenon Medical (TNON), Sintx Technologies (SINT), T2 Biosystems (TTOO), Heart Test Laboratories (HSCS), and Autonomix Medical (AMIX). These companies are all part of the "medical equipment" industry. Bluejay Diagnostics vs. Plus Therapeutics Star Equity Carmell Nuwellis Check-Cap Tenon Medical Sintx Technologies T2 Biosystems Heart Test Laboratories Autonomix Medical Plus Therapeutics (NASDAQ:PSTV) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends. Which has more risk & volatility, PSTV or BJDX? Plus Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Which has stronger earnings & valuation, PSTV or BJDX? Bluejay Diagnostics has lower revenue, but higher earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPlus Therapeutics$4.91M1.44-$13.32M-$2.53-0.47Bluejay Diagnostics$250K7.59-$9.95M-$1.37 thousand0.00 Do analysts recommend PSTV or BJDX? Plus Therapeutics presently has a consensus price target of $13.50, suggesting a potential upside of 1,025.00%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Plus Therapeutics is more favorable than Bluejay Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Bluejay Diagnostics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor PSTV or BJDX? Plus Therapeutics received 66 more outperform votes than Bluejay Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Bluejay Diagnostics an outperform vote while only 62.39% of users gave Plus Therapeutics an outperform vote. CompanyUnderperformOutperformPlus TherapeuticsOutperform Votes6862.39% Underperform Votes4137.61% Bluejay DiagnosticsOutperform Votes266.67% Underperform Votes133.33% Do insiders and institutionals hold more shares of PSTV or BJDX? 3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 5.5% of Plus Therapeutics shares are held by company insiders. Comparatively, 0.4% of Bluejay Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is PSTV or BJDX more profitable? Bluejay Diagnostics has a net margin of 0.00% compared to Plus Therapeutics' net margin of -225.07%. Plus Therapeutics' return on equity of 0.00% beat Bluejay Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Plus Therapeutics-225.07% N/A -154.56% Bluejay Diagnostics N/A -155.67%-117.82% Does the media favor PSTV or BJDX? In the previous week, Plus Therapeutics had 4 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 4 mentions for Plus Therapeutics and 0 mentions for Bluejay Diagnostics. Plus Therapeutics' average media sentiment score of 0.16 beat Bluejay Diagnostics' score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Plus Therapeutics Neutral Bluejay Diagnostics Neutral SummaryPlus Therapeutics beats Bluejay Diagnostics on 11 of the 18 factors compared between the two stocks. Get Bluejay Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for BJDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BJDX vs. The Competition Export to ExcelMetricBluejay DiagnosticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.95M$4.71B$5.84B$9.14BDividend YieldN/A39.90%4.75%3.85%P/E Ratio0.0028.1526.0419.11Price / Sales7.5953.22447.4676.36Price / CashN/A51.1038.0134.83Price / Book0.006.577.644.62Net Income-$9.95M$90.13M$3.18B$245.85M7 Day Performance-2.68%-2.23%-2.00%-2.61%1 Month Performance-4.70%-2.18%-0.44%-2.14%1 Year Performance-98.88%15.21%16.44%12.98% Bluejay Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BJDXBluejay DiagnosticsN/A$3.45-2.3%N/A-98.9%$1.95M$250,000.000.009Negative NewsPSTVPlus Therapeutics2.7838 of 5 stars$1.22-1.3%$13.50+1,006.5%-40.9%$7.20M$4.91M-0.4820News CoverageSTRRStar Equity1.0393 of 5 stars$2.11+2.4%N/A-53.9%$6.79M$45.78M-0.82460Gap UpCTCXCarmellN/A$0.28-9.2%N/A-92.2%$5.90MN/A0.0014NUWENuwellis1.8028 of 5 stars$1.33+4.7%$17.00+1,178.2%-94.0%$5.81M$8.86M-0.0170News CoverageGap DownCHEKCheck-Cap0.4475 of 5 stars$0.90-2.2%N/A-68.1%$5.27MN/A-0.3080Analyst ForecastTNONTenon Medical1.6786 of 5 stars$1.46-2.3%$5.50+278.0%+23.0%$4.57M$2.93M-0.058SINTSintx Technologies1.0023 of 5 stars$3.06-5.6%N/A-82.2%$4.10M$2.63M-0.0640News CoverageTTOOT2 Biosystems1.9574 of 5 stars$0.19-7.4%$5.00+2,472.0%-96.8%$4.09M$7.68M0.00180Analyst ForecastNews CoverageHigh Trading VolumeHSCSHeart Test Laboratories2.4807 of 5 stars$3.59-5.5%$13.50+276.0%-69.2%$3.52M$20,000.00-0.4510Positive NewsGap DownAMIXAutonomix Medical1.8583 of 5 stars$2.72+0.7%$28.00+929.4%-96.2%$3.13MN/A-0.171News Coverage Related Companies and Tools Related Companies Plus Therapeutics Alternatives Star Equity Alternatives Carmell Alternatives Nuwellis Alternatives Check-Cap Alternatives Tenon Medical Alternatives Sintx Technologies Alternatives T2 Biosystems Alternatives Heart Test Laboratories Alternatives Autonomix Medical Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BJDX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bluejay Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bluejay Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
